Article Contents ::
- 1 The Brand Name AZIPRO REDIUSE Has Generic Salt :: Azithromycin
- 2 AZIPRO REDIUSE Is From Company Cipla Priced :: Rs. 31.6
- 3 AZIPRO REDIUSE have Azithromycin is comes under Sub class Macrolides of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Macrolides
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name AZIPRO REDIUSE Has Generic Salt :: Azithromycin
AZIPRO REDIUSE Is From Company Cipla Priced :: Rs. 31.6
AZIPRO REDIUSE have Azithromycin is comes under Sub class Macrolides of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Macrolides
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler’s diarrhea,
Drug Dose ::
Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy. Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days.
Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
Drug Precautions ::
May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
Drug Side Effects ::
GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels. Potentially Fatal: Angioedema and cholestatic jaundice.
Pregnancy category ::
Drug Mode of Action ::
Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
Drug Interactions ::
Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity. Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.